AUTL Autolus Therapeutics ADS

Autolus Therapeutics to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5

Autolus Therapeutics to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5

LONDON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2020 financial results and operational highlights before open of U.S. markets on Thursday, November 5, 2020.

Management will host a conference call and webcast at 8:30 am ET/1:30 pm GMT to discuss the company’s financial results and provide a general business update. To listen to the webcast and view the accompanying slide presentation, please go to: .

The call may also be accessed by dialing (866) 679 5407 for U.S. and Canada callers or (409) 217-8320 for international callers. Please reference conference ID 5562455. After the conference call, a replay will be available for one week. To access the replay, please dial (855) 859-2056 for U.S. and Canada callers or (404) 537-3406 for international callers. Please reference conference ID 5562455.

Contact:

Lucinda Crabtree, PhD

Vice President, Investor Relations and Corporate Communications

+44 (0) 7587 372 619

Julia Wilson

+44 (0) 7818 430877

Susan A. Noonan

S.A. Noonan Communications



EN
30/10/2020

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

Jacob Mekhael
  • Jacob Mekhael
GLPG GALAPAGOS NV
AUTL Autolus Therape... ... (+3)

ASH abstracts: Autolus, Galapagos, MaaT

The abstracts for presentations at the American Society of Haematology conference (ASH, 6-9 December) became available yesterday during the day (HERE). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (new data for Aucatzyl in paediatric ALL, real world data in adult ALL, amongst others), Galapagos (additional CAR-T data in r/r MCL and r/r DLBCL) and MaaT (longer follow up from ...

GLPG GALAPAGOS NV
AUTL AUTOLUS THERAPEUTICS ADS
MAAT MAAT PHARMA SA
11/04/25 November 4, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics to Present Clinical Data Updates at the American ...

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025 LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of five abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held December 6-9, 2025, in Orlando, Florida. “Data to be presented at the upcoming ASH Annual Meeting con...

November 3, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics to Report Third Quarter 2025 Financial Results an...

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its third quarter 2025 financial results and operational highlights before open of U.S. markets on Wednesday, November 12, 2025. Management will host a conference call and webcast at 8:30am EST / 1:30pm...

October 30, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
AUTL Autolus Therape...

Autolus Aucatzyl phase 1 maintains SLE responses with longer follow up

Autolus announced that follow-up data from the ongoing phase 1 (CARLYSLE) dose confirmation trial of Aucatzyl (obe-cel, CD19 CAR-T) in severe refractory systemic lupus erythematosus (srSLE), will be presented during a poster session at the American College of Rheumatology Convergence 2025. The updated results demonstrate durability of outcomes observed in the initial readout (presented April 2025) over a longer follow up period as evidenced by the absence of new disease activity, no other lupus ...

AUTL AUTOLUS THERAPEUTICS ADS
10/28/25 October 28, 2025 1 EN
Jacob Mekhael ... (+3)
  • Jacob Mekhael
  • Michiel Declercq
  • Thomas Couvreur
KPN ROYAL KPN NV
BFIT BASIC-FIT NV
AUTL AUTOLUS THERAPEUTICS ADS
HYL HYLORIS PHARMACEUTICALS
10/28/25 October 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch